2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3211

Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands
Abstract Number: 3212

Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?
Abstract Number: 3213

Assessment of Two Different DAS Treatment Targets in Early Active Rheumatoid Arthritis Patients
Abstract Number: 3214

Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative
Abstract Number: 3215

ASK1 Is Regulated By IL-1β and TNF and Modulates Key Rheumatoid Arthritis (RA) Fibroblast-like Synoviocyte Functions (FLS)
Abstract Number: 3216

Integrated High-Dimensional Analyses Reveal a Pathologically Expanded ‘Peripheral’ B Cell-Helper T Cell Population in Rheumatoid Arthritis
Abstract Number: 3217

Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Abstract Number: 3218

Synovial Mast Cells Associate with High Disease Activity and Predict Radiographic Progression at 12 Months in Patients with Early Rheumatoid Arthritis
Abstract Number: 3219

Altered microRNA Expression Pattern in Synovial and Blood Neutrophils in Rheumatoid Arthritis Reveals the Pathogenic Profile of These Cells. Effect of Biological Therapies
Abstract Number: 3220

Distinct Single Cell Gene Expression Signatures of Monocyte Subsets Differentiate Between TNF-Alpha Inhibitor Treatment Response Groups in Rheumatoid Arthritis
Abstract Number: 3221

Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-Blind, Monotherapy Study in Patients with Active Rheumatoid Arthritis with Intolerance or Inadequate Response to Methotrexate
Abstract Number: 3222

Efficacy and Safety of Monotherapy with Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study
Abstract Number: 3223

Efficacy and Safety of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
Abstract Number: 3224

Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Based upon Prior Use of Non-Anti-TNF Biologics in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global Phase 3 Study
Abstract Number: 3225

Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].